Objectives: The Pipeline Embolization Device (PED) is a flow diverter system designed to treat intracranial aneurysms. This study focuses on unruptured, wide neck, giant intracranial aneurysm, and aims at identifying the cost-effectiveness of PED compared with current standard therapies available in the Mexican public healthcare system. MethOds: To predict clinical endpoints and costs over a 15-year time horizon, a decision analytic model (Markov) was developed. The model has a short-term component with three health states based on major radiologic outcomes: complete occlusion, residual neck, and residual aneurysm; and a longterm component with three health states: reintervention, rupture and death. The endovascular procedures of coiling and stent assisted coiling were identified as comparators. Clinical efficacy was measured using radiological outcomes; all clinical trials used the same assessment tools facilitating comparison. Costs were taken from public available sources considering direct medical costs only. Results were presented as incremental cost per life years gained in national currency. Results: PED showed to have an ICER of $103,839.34 versus coiling, 117,043.87 when compared to stent-assisted coiling and $20,711.69 when compared with the no intervention strategy in a 15-year temporal horizon scenario. PED obtained an ICER below Mexican GDP threshold per life years gained, versus the rest of the competitors in the mentioned timeline. Other ICERs for different time horizons will be shown in the sensitivity analysis. cOnclusiOns: PED represents a cost-effective strategy for the treatment of this particular type of aneurysmal lesions when compared with the current available endovascular treatment options in the Mexican public healthcare system. Objectives: To investigate the long-term cost-effectiveness of initiating transanal irrigation* (TAI) in patients with neurogenic bowel dysfunction (NBD) who have failed standard bowel care (SBC) from a Medicare payer perspective in the United States (US). MethOds: A Markov decision model was used to projects the lifetime health economic outcomes, including quality-adjusted life years (QALY), episodes of fecal incontinence (FI), urinary tract infections (UTIs), and stoma surgery when using TAI relative to continuing SBC. Current clinical experience in the US is limited to a dataset of 24 spina bifida patients. Therefore transition probabilities and QALY estimates were based on a larger UK data set including 227 patients with NBD due to spinal cord injury (SCI), multiple sclerosis, spina bifida, and cauda equina syndrome. A Medicare payer perspective was applied for cost collection, and for diagnosisrelated group procedures, the median of the averages of what each New Jersey health care provider received in total payments was used. Projected life-expectancy was based on published SCI population data. Results: The model predicts that an SCI patient diagnosed at age 30, with a life expectancy of 37 years using TAI, will experience a 36.1% reduction in FI, a 28.7% reduction in UTIs, a 35.4% reduction in stoma surgery and an improvement of 0.40 QALY, compared with patients continuing SBC. Lifetime cost-savings of $1,293 per patient was estimated for TAI versus SBC in a SCI patient, primarily due to avoided hospitalizations and stoma surgeries. Incremental cost is influenced by life-expectancy (and age of diagnosis) in the patient cohort. cOnclusiOns: TAI is a cost-saving treatment strategy from a Medicare perspective and reduces risk of stoma surgery, fecal incontinence and UTIs whilst improving QALY for NBD patients who have failed SBC. *Peristeen (Coloplast A/S).
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PMD39 HEMODIALYSIS REVERSE OSMOSIS MACHINES DISINFECTION VERSUS NEW PURCHASE: COST-EFFECTIVENESS ANALYSIS
Yassin M. H. , Smith K. J. University of Pittsburgh, Pittsburgh, PA, USA Objectives: Hemodialysis (HD) is the standard of care for end stage renal disease patients. Reverse osmosis (RO) technology was designed to improve HD water safety. Strict guidelines regulate RO machine infection control. If required standards are not met, the machine is pulled Out Of Service (OOS), with repeated disinfection and culture performed before it can Return To Use (RTU). With repeated disinfection failures, purchase of a new machine may need to be considered; the cost-effectiveness of decision options is unclear. MethOds: A Markov model estimated the cost effectiveness of continued disinfection for a RO machine repeatedly failing to meet standards vs. purchase of a new machine over a 5 year machine lifespan. The model considered probabilities of remaining OOS after disinfection and of patient infection after RTU post disinfection, as well as costs of disinfection and RO purchase. Costs per patient infection avoided were calculated, taking a hospital perspective and testing result robustness in sensitivity analyses. We estimate that hospitals would pay at least $1 million per dialysis-related infection avoided, due to infection costs and the potential costs of liability and diminished reputation. Results: In the base case, new machine purchase after 5 failed disinfections was least costly and least effective. Compared to this strategy, purchase after 4 failed disinfections cost $682,000/ infection avoided. Purchasing after 3, 2, or 1 failed disinfection cost $2.1 million, $6.1 million, or $15.9 million per patient infection avoided, respectively. Purchase after 5 failed disinfections was favored if patient infection risk was substantially lower or new machine purchase cost > $14,365 (base case $10,000). cOnclusiOns: RO machine purchase after 4 failed disinfections is a favorable strategy at a $1 million/ patient infection avoided threshold. Purchase after fewer failed disinfections may be favored if willingness-to-pay thresholds are higher. becomes an option for certain patients but cost becomes an important issue. We performed a systematic review of the literature of economic studies of the use of DBS in patients with PD, including costs studies or economic evaluations expressed as cost per improvement in quality life, decrease in dose of pharmacological treatments or the decrease of carer burden. MethOds: We reviewed the following databases: Medline/Pubmed, Embase, Cochrane Database of Systematic Reviews, LILACS, Cochrane Central Register of Controlled Trials, WHO International Clinical Trials Registry Platform ICTRP portal and ClinicalTrials.gov from 1980 to 2015. Results: From the original 2120 references retrieved, 9 studies were selected. There were two studies coming from United States, Germany, and Spain, and one each from China, Italy, and United Kingdom. The average cost of DBS for a patient with PD in five years is € 181.086. QALYs gained were higher in DBS compared to best medical treatment (BMT) after at least two years of treatment with an average ICUR € 31.655 and an incremental cost of € 40.679/QALY gained. However, DBS clearly has a higher cost at year 1. cOnclusiOns: DBS is a cost-effective intervention for patients with advanced PD but has a high initial cost compared to BMT. However, DBS reduces costs on pharmacological treatment and evidence suggests it also reduces direct, indirect and social costs of PD on the long term. Objectives: Cost-Effectiveness analysis of cryoablation (CA) vs. conventional radio-frequency (RF) pulmonary vein isolation for the treatment of patients with paroxysmal atrial fibrillation (AF) in Colombia. MethOds: An analytical decision model was considered with 1-year freedom from recurrent AF (FAF) and total direct medical cost including specific procedure complications as end points. Excel platform and VB was used to develop the model. Effectiveness data as well as specific procedure complications were obtained from literature review. A payer perspective and 1-year horizon was assumed. Total costs for procedure and complications were taken from reimbursement values charged to payers. Uncertainty adjustment was applied to complications probability. Because effectiveness and cost were taken as unique values at the end of the 1-year, discount rate was no applied. A second intervention after treatment failure was assumed. The sensitivity Univariate analysis was done. For the Probabilistic Sensitivity Analysis a Monte Carlo Simulation with 1000 iterations was done. Results: The total costs including procedure, complications expected value and re-intervention was USD$12.766 for CA vs. USD$14.751 for RF. The effectiveness for CA was 84% 1-year freedom from AF compared to 68% for RF. Therefore, CA was dominant to RF. Univariate sensitivity analysis with Tornado diagram showed an ICER particularly sensitive to the price of the procedure and the effectiveness of CA and RF. The probabilistic sensitivity analysis showed a robust model. cOnclusiOns: CA with a lower total costs and higher effectiveness in terms of 1-year freedom from AF was dominant to RF. The Univariate sensitivity analysis shows an ICER particularly sensitive to procedure costs and effectiveness. Villeurbanne, France, 3 Semmelweis University, Budapest, Hungary, 4 Cancer Centre Léon Bérard, Lyon, France Objectives: Breast cancer is the most frequently diagnosed cancer worldwide and the leading cause of cancer death among women. High levels of ZNF217 mRNA represent a new biomarker for poor prognosis associated with shorter relapse-free survival (RFS) in breast cancer. This study aimed to assess the cost-effectiveness of ZIRA Test for breast cancer patients in France, having the great advantage of dispensing the appropriate treatment to patient, avoiding unnecessary chemotherapy with associated adverse events and improving quality of life. MethOds: The costeffectiveness and cost-utility analyses concerns a breast cancer sub-population, with early Breast-Stage Cancer (ESBC), positive endocrine response (ER+), negative response for the protein human epidermal growth factor receptor 2 (HER2-) test, negative or positive lymph node axillary, without neo-adjuvant treatment. A Markov model was defined at 10 years. Markov states were: relapse-free survival, loco-regional, recurrence, distant recurrence, and death. The perspective of the French national insurance was retained. The Kruppel-like factor (KMP) cohort, resulted from a metaanalysis of gene-expression profiles from 1,080 primary breast cancer specimens who had not received any therapy before surgery and with known clinical follow-up, was used. Costs of treatments were based on the French diagnoses-related groups and from the Classification Commune des Actes Médicaux. The cost of the genomic test ZNF217 was assessed using a micro-costing approach. Cost-effectiveness results were expressed in terms of the incremental cost per relapse-free life years gained and cost per QALY gained. The robustness of results and uncertainty was assessed using univariate and probabilistic sensitivity analyses. Results: The costs were estimated at € 5,087 for the ZIRA Test strategy and € 4,833 for the usual care strategy. Incremental cost-effectiveness ratio was € 473 per relapse-free year gained. cOnclusiOns: Within French settings, the ZIRA Test strategy appears cost-effective in Early Breast-Stage Cancer patients.
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